Lixte Biotechnology Holdings- Warrants (01/01/2025) Operating Income

Lixte Biotechnology Holdings- Warrants (01/01/2025) (LIXTW) currently reports a operating income of $-5.1B as of June 2026. That compares with $-3.1M in the prior-year period — down 165905.3% year over year. Use the charts on this page to explore Lixte Biotechnology Holdings- Warrants (01/01/2025)'s operating income history and peer comparisons.

Lixte Biotechnology Holdings- Warrants (01/01/2025)'s operating income decreased from $-3.1M to $-5.1B — a 165905.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lixte Biotechnology Holdings- Warrants (01/01/2025) reported $-5.1B in operating income as of June 2026. That compares with $-3.1M in the prior-year period — down 165905.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-5.1B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lixte Biotechnology Holdings- Warrants (01/01/2025), and consider following LIXTW for alerts when major investors trade the stock.

Lixte Biotechnology Holdings- Warrants (01/01/2025) is classified in the Healthcare sector. On operating income, it currently shows $-5.1B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LIXTW with unrelated industries.